SNY vs TECH
Sanofi vs Bio-Techne — AI-powered side-by-side comparison
| Metric | SNY | TECH |
|---|
| AI Score |
68
|
71
|
| Price |
$43.70
|
$72.42
|
| P/E Ratio |
23.09×
|
61.88×
|
| ROE |
10.9%
|
8.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.8%
|
65.8%
|
| Debt / Equity |
0.34×
|
0.13×
|
| Dividend Yield |
5.5%
|
0.4%
|
| RSI (14) |
56.9
|
63.6
|
| Beta |
0.278
|
1.277
|
| Expected Upside |
+3.5%
|
—
|
AI Committee View
Current Innellis committee reasoning for SNY versus TECH.
TECH leads by 3 points.
TECH scores 71/100 (Buy) versus SNY at 68/100 (Buy).
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is eps declining -37.4% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 5.4% pays you to wait — Value
- Revenue growing 39.5% YoY -- genuine top-line momentum — Growth
Bear Case
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
TECH Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical